Skip to main content

Table 5 Adverse events of the neoadjuvant therapy group

From: Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery

Adverse events

Rate

Pneumonia

0/34

Myocarditis

0/34

Liver damage

0/34

Renal damage

0/34

Endocrine disorder

3/34

Dermatitis

1/34

Leucopenia

6/34

Back to article page

Journal of Cardiothoracic Surgery

ISSN: 1749-8090

Contact us